Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
Type:
Grant
Filed:
November 6, 2009
Date of Patent:
January 24, 2012
Assignee:
Galaxy Biotech, LLC
Inventors:
Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
Abstract: The present invention is related to antibodies with binding affinity to fibroblast growth factor receptor 2 (FGFR2) optionally with binding affinity to other FGF receptors, which block both ligand-dependent and constitutive ligand independent receptor activation. Specifically, the present invention relates to antibodies with high affinity to more than one FGF receptor subtype, and fragments thereof, useful in treating disorders including cell proliferative diseases.
Abstract: This disclosure characterizes the function and the expression of the human protein encoded by tm9sf4. The protein is highly expressed in malignant tumor cells and therefore is a novel marker for malignancy. Moreover, the protein is involved in the phagocytotic character of tumor cells. This disclosure provides methods and tools to diagnose and follow up malignancy of tumors. Furthermore, means to inhibit phagocytotic character of tumor cells as well as means to treat cancer are provided.
Abstract: The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP.
Type:
Grant
Filed:
June 7, 2005
Date of Patent:
January 10, 2012
Assignees:
Kyowa Hakko Kirin Co., Ltd, Japan as represented by President of National Cancer Center
Abstract: An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene.
Type:
Grant
Filed:
December 6, 2006
Date of Patent:
January 10, 2012
Assignees:
Kyowa Hakko Kirin Co., Ltd., Japan as Represented by President of National Cancer Center
Abstract: Methods useful for human adapting non-human monoclonal antibodies are disclosed. The methods select candidate human antibody framework sequences from a human germline framework database.
Abstract: The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.
Type:
Grant
Filed:
September 26, 2007
Date of Patent:
January 3, 2012
Assignees:
The United States of America as represented by the Department of Health and Human Services, Immunocore Limited
Inventors:
Paul F. Robbins, Richard A. Morgan, Steven A. Rosenberg, Alan David Bennett
Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.
Type:
Grant
Filed:
December 21, 2005
Date of Patent:
December 27, 2011
Assignee:
Viventia Biotechnologies Inc.
Inventors:
Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Francina C. Chahal
Abstract: The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an IG-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct is provided. Further aspects of the invention are vectors and host cells comprising the nucleic acid sequences, a process for the production of the construct and composition comprising the construct. The invention also provides the use of the constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
Type:
Grant
Filed:
October 15, 2004
Date of Patent:
December 13, 2011
Assignee:
Micromet AG
Inventors:
Robert Hofmeister, Birgit Kohleisen, Ulla Lenkkeri-Schütz, Christian Itin, Patrick Bäuerle, Francis J. Carr, Anita A. Hamilton, Stephen Williams
Abstract: The present invention relates to novel isolated antibodies, derived compounds, and functional isolated antibody fragments, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo and obtained by functional screening. More particularly, the present invention relates to the 6F4 antibody, specific to the JAM-A protein, as well as its use for the treatment of cancer. Pharmaceutical compositions composed of these antibodies are also covered.
Abstract: The present invention refers to a method of treating tumor growth and metastasis in a mammal, the treating comprising administering allogeneic effector cells together with trifunctional bispecific or trispecific antibodies or a combination thereof having the following properties: a) binding to a T cell b) binding to at least one antigen on a tumor cell c) binding via their Fc portion in the case of trifunctional bispecific antibodies or via third specificity in the case of trispecific antibodies to Fc receptor positive cells; the antibodies redirecting the allogenic cells away from host tissues in order to substantially reduce or avoid a graft versus host disease.
Abstract: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.
Type:
Grant
Filed:
October 24, 2008
Date of Patent:
November 29, 2011
Assignee:
Lpath, Inc.
Inventors:
Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
Abstract: A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween.
Type:
Grant
Filed:
July 25, 2008
Date of Patent:
November 29, 2011
Assignee:
Novagen Holding Corporation
Inventors:
Haitao Wang, Yong Du, Rui Zhang, Jing Xu, Longbin Liu
Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
Type:
Grant
Filed:
April 19, 2006
Date of Patent:
November 29, 2011
Assignee:
Seattle Genetics, Inc.
Inventors:
Charlotte McDonagh, Paul Carter, Julie McEarchern, Che-Leung Law
Abstract: Compositions comprising a tissue vaccine that include a mixture of heterogeneous tissue obtained from tumors and connective tissues. Vaccines comprising these compositions are also provided, as well as methods of using the vaccines in the treatment and/or inhibition of tumor growth, and particularly prostate tumor growth and cancers. The preparations may be defined as vaccines comprising tumor cells and connective (stromal) tissues derived from xenogeneic animals. Preparations comprising the tissue vaccines are provided using tissue harvested directly from tumors. Methods for preventing de novo development of cancer are also disclosed. A tissue vaccine comprising glutaraldehyde-(GFT) treated tissue prepared from tumor and connective tissue reduces the incidence of autochthonous prostate cancer. A tissue vaccine comprising a potassium thiocyanate extract (PTE) preparation of a tumor and connective tissue is also provided.
Type:
Grant
Filed:
October 25, 2007
Date of Patent:
November 22, 2011
Assignee:
University of Notre Dame
Inventors:
Mark A. Suckow, William R. Wolter, Morris Pollard
Abstract: A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.
Type:
Grant
Filed:
September 8, 2009
Date of Patent:
November 15, 2011
Assignees:
Astrazeneca AB, Dyax Corporation
Inventors:
Christer Nordstedt, Tom Goldschmidt, Maria Henderikx, René Hoet, Henricus Hoogenboom, Simon Hufton, Christin V. Andersson, Johanna Lindquist, Dan Sunnemark, Sergy Leonov
Abstract: The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.
Type:
Grant
Filed:
September 17, 2008
Date of Patent:
November 15, 2011
Assignee:
Immunomedics, Inc.
Inventors:
Hans Hansen, Zhengxing Qu, David M. Goldenberg
Abstract: The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the agents are therapeutic, diagnostic, or research agents.
Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
Type:
Grant
Filed:
December 1, 2008
Date of Patent:
October 25, 2011
Assignee:
KaloBios Pharmaceuticals, Inc.
Inventors:
Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
Type:
Grant
Filed:
March 9, 2007
Date of Patent:
October 25, 2011
Assignee:
Wyeth LLC
Inventors:
Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil Sreekumar